{"id":476100,"date":"2021-04-14T08:04:11","date_gmt":"2021-04-14T12:04:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/"},"modified":"2021-04-14T08:04:11","modified_gmt":"2021-04-14T12:04:11","slug":"ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/","title":{"rendered":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Ardelyx to Receive a $5 Million Milestone Payment<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>FREMONT, Calif.\u00a0and <span class=\"xn-location\">WALTHAM, Mass.<\/span>, <span class=\"xn-chron\">April 14, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that its collaboration partner in <span class=\"xn-location\">Japan<\/span>, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in <span class=\"xn-location\">Japan<\/span> evaluating tenapanor for hyperphosphatemia. The achievement of this development milestone triggers a <span class=\"xn-money\">$5 million<\/span> payment to Ardelyx. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg\" title=\"Ardelyx logo (PRNewsFoto\/Ardelyx) (PRNewsfoto\/Ardelyx)\" alt=\"Ardelyx logo (PRNewsFoto\/Ardelyx) (PRNewsfoto\/Ardelyx)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The Phase 3 clinical trials consist of a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparative study; a phosphate binder-combination parallel-group comparative study; an open-label, single-arm study evaluating hyperphosphatemia patients on peritoneal dialysis; and a long-term study evaluating serum phosphorus in patients who switch from one or more phosphate binders to tenapanor for hyperphosphatemia in <span class=\"xn-location\">Japan<\/span>. \u00a0<\/p>\n<p>&#8220;As we approach our <span class=\"xn-chron\">April 29<\/span> PDUFA date for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis and prepare for potential commercialization in the U.S., we are pleased to see the significant progress made by our partner Kyowa Kirin,&#8221;\u00a0said <span class=\"xn-person\">Mike Raab<\/span>, president and chief executive officer of Ardelyx. &#8220;We are thrilled to have key strategic partners like Kyowa Kirin, along with our partners in <span class=\"xn-location\">Canada<\/span> and <span class=\"xn-location\">China<\/span>, to support development of, and once approved, patient access to, tenapanor globally.&#8221;<\/p>\n<p>Under the terms of the license agreement <span id=\"spanHghltcae3\">for\u00a0tenapanor\u00a0with Kyowa Kirin, which was signed in 2017<\/span>\u00a0Ardelyx received a <span class=\"xn-money\">$30 million<\/span> upfront payment and is eligible to receive up to <span class=\"xn-money\">$55.0 million<\/span> in total development milestones and <span class=\"xn-money\">8.5 billion yen<\/span> in commercialization milestones. Ardelyx is also eligible to receive high-teen royalties on sales throughout the term of the agreement. Kyowa Kirin has been granted the exclusive rights to develop, market and commercialize tenapanor for cardiorenal diseases and conditions associated with them, including hyperphosphatemia, in <span class=\"xn-location\">Japan<\/span>. <\/p>\n<p>\n        <b>About Tenapanor for Hyperphosphatemia<br \/><\/b>Tenapanor, discovered and developed by Ardelyx, is a first-in-class, proprietary, oral medicine for which an NDA is under review by the FDA for the control of serum phosphorus in adult patients with CKD on dialysis. Tenapanor has a unique mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). This results in a conformational change of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate at the primary pathway of phosphate absorption. Ardelyx is conducting NORMALIZE, an ongoing extension study of the PHREEDOM Phase 3 monotherapy study, which is designed to evaluate the ability of tenapanor, as monotherapy or in combination with sevelamer, to achieve serum phosphorus levels in the normal range (2.5 \u2013 4.5 mg\/dL) in patients with chronic kidney disease (CKD) on dialysis. Planned analyses have demonstrated that the use of tenapanor as a foundational approach, as monotherapy or in combination with sevelamer carbonate, produces a significant phosphorus-lowering effect. After ~ 20 months of treatment with tenapanor alone or with low doses of sevelamer, patients exhibited a mean serum phosphorus reduction of 2.33 mg\/dL, from a mean baseline phosphorus of 7.27 mg\/dL at the beginning of the PHREEDOM trial to a mean of 4.94 mg\/dL.<\/p>\n<p>\n        <b>About Ardelyx, Inc.<br \/><\/b>Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company&#8217;s NDA is currently under review by the FDA, with a PDUFA date of <span class=\"xn-chron\">April 29, 2021<\/span>. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and\/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA<sup>\u00ae<\/sup> (tenapanor) on <span class=\"xn-chron\">September 12, 2019<\/span>. Ardelyx has established agreements with Kyowa Kirin in <span class=\"xn-location\">Japan<\/span>, Fosun Pharma in <span class=\"xn-location\">China<\/span> and Knight Therapeutics in <span class=\"xn-location\">Canada<\/span> for the development and commercialization of tenapanor in their respective territories.<\/p>\n<p>\n        <b>Forward Looking Statements<br \/><\/b>To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for tenapanor in controlling serum phosphorus in chronic kidney disease patients on dialysis as monotherapy or in combination with Sevelamer carbonate. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelia&#8217;s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties associated with the drug development, regulatory approval and commercialization process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelia&#8217;s business in general, please refer to Ardelia&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on <span class=\"xn-chron\">March 8, 2021<\/span>, and its future current and periodic reports to be filed with the Securities and Exchange Commission.<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF40331&amp;sd=2021-04-14\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan-301268341.html\">http:\/\/www.prnewswire.com\/news-releases\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan-301268341.html<\/a><\/p>\n<p>SOURCE  Ardelyx<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF40331&amp;Transmission_Id=202104140800PR_NEWS_USPR_____SF40331&amp;DateId=20210414\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ardelyx to Receive a $5 Million Milestone Payment PR Newswire FREMONT, Calif.\u00a0and WALTHAM, Mass., April 14, 2021 \/PRNewswire\/ &#8212;\u00a0Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia. The achievement of this development milestone triggers a $5 million payment to Ardelyx. The Phase 3 clinical trials consist of a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparative study; a phosphate binder-combination parallel-group comparative study; an open-label, single-arm study evaluating hyperphosphatemia patients on peritoneal dialysis; and a long-term study evaluating serum &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476100","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ardelyx to Receive a $5 Million Milestone Payment PR Newswire FREMONT, Calif.\u00a0and WALTHAM, Mass., April 14, 2021 \/PRNewswire\/ &#8212;\u00a0Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia. The achievement of this development milestone triggers a $5 million payment to Ardelyx. The Phase 3 clinical trials consist of a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparative study; a phosphate binder-combination parallel-group comparative study; an open-label, single-arm study evaluating hyperphosphatemia patients on peritoneal dialysis; and a long-term study evaluating serum &hellip; Continue reading &quot;Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-14T12:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan\",\"datePublished\":\"2021-04-14T12:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/\"},\"wordCount\":883,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1309911\\\/Ardelyx_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/\",\"name\":\"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1309911\\\/Ardelyx_Logo.jpg\",\"datePublished\":\"2021-04-14T12:04:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1309911\\\/Ardelyx_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1309911\\\/Ardelyx_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/","og_locale":"en_US","og_type":"article","og_title":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan - Market Newsdesk","og_description":"Ardelyx to Receive a $5 Million Milestone Payment PR Newswire FREMONT, Calif.\u00a0and WALTHAM, Mass., April 14, 2021 \/PRNewswire\/ &#8212;\u00a0Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia. The achievement of this development milestone triggers a $5 million payment to Ardelyx. The Phase 3 clinical trials consist of a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparative study; a phosphate binder-combination parallel-group comparative study; an open-label, single-arm study evaluating hyperphosphatemia patients on peritoneal dialysis; and a long-term study evaluating serum &hellip; Continue reading \"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-14T12:04:11+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan","datePublished":"2021-04-14T12:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/"},"wordCount":883,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/","name":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg","datePublished":"2021-04-14T12:04:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1309911\/Ardelyx_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476100"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476100\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}